首页|人血白蛋白用于心外科围术期管理的有效性和安全性Meta分析

人血白蛋白用于心外科围术期管理的有效性和安全性Meta分析

扫码查看
目的 为临床合理使用人血白蛋白(HSA)提供参考。方法 计算机检索The Cochrane Library、PubMed、Web of Science、中国知网、万方、维普数据库,收集HSA用于心外科围术期的随机对照试验(RCT),检索时限为自建库起至2023年8月31日。由2名研究员筛选文献,并提取资料。采用Cochrane系统评价手册5。1。0风险偏倚评估工具对纳入文献质量进行评价。采用RevMan 5。4软件进行Meta分析、敏感性分析和发表偏倚分析。结果 共纳入9项RCT,共计2 223例患者。Meta分析结果显示,与对照组比较,观察组全因死亡率[RR=1。55,95%CI(0。62,3。86),P=0。35]、住院时间[MD=-0。40,95%CI(-0。89,0。09),P=0。11]、入住重症监护室(ICU)时间[MD=-0。26,95%CI(-0。66,0。13),P=0。20]、机械通气持续时间[MD=-0。21,95%CI(-0。91,0。49),P=0。55]、红细胞输注率[RR=0。96,95%CI(0。68,1。36),P=0。82]、血小板输注率[RR=0。70,95%CI(0。42,1。17),P=0。17]、血浆输注率[RR=0。83,95%CI(0。50,1。40),P=0。49]、急性肾损伤发生率[RR=0。98,95%CI(0。62,1。57),P=0。94]差异均无统计学意义。亚组分析结果显示,4%HSA组患者出血量显著多于对照组[MD=141。55,95%CI(115。02,168。07),P<0。00001];5%HSA组患者出血量与对照组无统计学差异[MD=20。94,95%CI(-131。80,173。68),P=0。79]。发表偏倚结果显示,本研究存在发表偏倚的可能性较大。结论 当前证据表明,心外科围术期应用HSA不能显著改善患者的长期预后指标,减少血液制品的使用和降低不良反应发生风险;使用不同质量浓度的HSA,术后出血量可能不同。
Efficacy and Safety of Human Serum Albumin in Perioperative Management of Cardiac Surgery:A Meta-Analysis
Objective To provide a reference for the rational use of human serum albumin(HSA)in clinical practice.Methods The randomized controlled trials(RCTs)of HSA in perioperative period of cardiac surgery in The Cochrane Library,PubMed,Web of Science,CNKI,WanFang,and VIP databases from the inception of the database to August 31,2023 were searched.The literature was screened and data were extracted by two researchers.The quality of the included literature was evaluated by the risk bias assessment tool recommended by Cochrane Systematic Review Manual 5.1.0.Meta-analysis,sensitivity analysis and publication bias analysis were performed by the RevMan 5.4 software.Results Nine RCTs were included,involving 2 223 patients.Meta-analysis showed that the all-cause mortality[RR=1.55,95%CI(0.62,3.86),P=0.35],hospital stay[MD=-0.40,95%CI(-0.89,0.09),P=0.11],intensive care unit(ICU)stay[MD=-0.26,95%CI(-0.66,0.13),P=0.20],duration of mechanical ventilation[MD=-0.21,95%CI(-0.91,0.49),P=0.55],red blood cell infusion rate[RR=0.96,95%CI(0.68,1.36),P=0.82],platelet infusion rate[RR=0.70,95%CI(0.42,1.17),P=0.17],plasma infusion rate[RR=0.83,95%CI(0.50,1.40),P=0.49],incidence of acute kidney injury[RR=0.98,95%CI(0.62,1.57),P=0.94]in the observation group were similar with those in the control group.The subgroup analysis showed that the bleeding volume of patients in the 4%HSA group was significantly larger than that in the control group[MD=141.55,95%CI(115.02,168.07),P<0.000 01];the bleeding volume of patients in the 5%HSA group was similar with that in the control group[MD=20.94,95%CI(-131.80,173.68),P=0.79].The publication bias indicated that there was a high possibility of publication bias in this study.Conclusion Current evidence suggests that the use of HSA in the perioperative period of cardiac surgery does not significantly improve the long-term prognostic indicators,decrease the use of blood products and the risk of adverse reactions in patients.The volume of postoperative bleeding may vary with the use of different mass concentrations of HSA.

human serum albuminDepartment of Cardiac Surgeryperioperative periodefficacysafetyMeta-analysis

刘东华、郭延磊、王心怡、高彤、周长凯、李静

展开 >

青岛大学附属医院,山东青岛 266000

山东省青岛市即墨区田横岛省级旅游度假区卫生院,山东青岛 266209

人血白蛋白 心外科 围术期 有效性 安全性 Meta分析

2024

中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
年,卷(期):2024.33(24)